International Journal of Reproductive BioMedicine
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences of Yazd
Vol. 15, No. 7, 2017, pp. 429-434
Bioline Code: rm17054
Full paper language: English
Document type: Research Article
Document available free of charge
International Journal of Reproductive BioMedicine, Vol. 15, No. 7, 2017, pp. 429-434
© Copyright  - International Journal of Reproductive BioMedicine
Final follicular maturation by administration of GnRH agonist plus HCG versus HCG in normal responders in ART cycles: An RCT|
Eftekhar, Maryam; Mojtahedi, Maryam Farid; Miraj, Sepideh & Omid, Malihe
Background: Gonadotropin-releasing hormone agonists (GnRH-a) was increasingly
used for triggering oocyte maturationfor the prevention of ovarian hyperstimulation
syndrome. Studies suggest that GnRH-a might be used as a better trigger agent since
it causes both Luteinizing hormone and follicle stimulating hormone release from a
physiologic natural cycle.
Objective: The aim of this study was to evaluate the effect of dual-triggering in
assisted reproductive technology outcomes.
Materials and Methods: 192 normal responder women aged ≤42 years and 18<
Body Mass Index <30 kg/m2 enrolled in this single-blind randomized controlled
trial. All participants received antagonist protocol. For final triggering, women
randomly were divided into two groups. Group, I was triggered by 6500 IU human
chorionic gonadotropin (hCG) alone, and group II by 6500 IU hCG plus 0.2 mg of
triptorelin. The implantation, chemical, clinical and ongoing pregnancy, and
abortion rates were measured.
Results: The mean of retrieved oocytes and obtained embryos were statistically
higher in the dual-trigger group (group I), but the implantation and pregnancy rates
were similar in two groups.
Conclusion: The results of our study did not confirm the favorable effect of dual-triggered
oocyte maturation with a GnRH-a and a standard dosage of hCG as an
effective strategy to optimize pregnancy outcome for normal responders in GnRH-antagonist
cycles. We think that this new concept requires more studies before
becoming a universal controlled ovarian hyperstimulation protocol in in vitro
Trigger; Gonadotropin-releasing hormone; Agonist; Antagonist; Normal responder; Human chorionic gonadotropin.
Alternative site location: http://www.ijrm.ir